By Donna Loyle, communications specialist, LIMR
Researchers at Main Line Health and other sites are studying the safety and efficacy of adding the FDA-approved oral drug Venclexta® (venetoclax) to treatment regimens for patients aged 18 to 70 who have been diagnosed with chronic lymphocytic leukemia (CLL).
All participants in this phase III clinical trial receive Imbruvica® (ibrutinib) and Gazyva® (obinutuzumab), drugs that are FDA approved to treat CLL. One group of patients is then randomized to also receive venetoclax.
Eligible patients must not have been treated previously with chemotherapy, BTK inhibitors, venetoclax, small molecule signaling inhibitors or monoclonal antibodies for treatment of CLL.
Other inclusion and exclusion criteria apply. See the website for more details.
Study #EA9161is approved for Lankenau Medical Center and Paoli Hospital. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email email@example.com or visit https://www.mainlinehealth.org/research/clinical-trials/ea9161